Researching safety and cost-effectiveness in the life cycle of nanomedicine.
Nanotechnology is rapidly emerging as a transformational influence on many industry sectors. This is particularly true of medicines and medical devices. This article argues that, as policy interest in devising an appropriate regulatory framework for nanotherapeutics escalates, it will be important for public health to ensure that a broad life-cycle approach to both safety and cost-effectiveness is adopted. It charts some of the most important issues likely to be faced and begins to map how they can best be addressed.
Faunce
Thomas
T
Medical School and College of Law, The Australian National University, Canberra, ACT. Thomas.Faunce@anu.edu.au
Shats
Kathy
K
D001315:Australia; D001709:Biotechnology / Q000191:economics* / Q000331:legislation & jurisprudence; D003362:Cost-Benefit Analysis; D033161:Government Regulation; D006302:Health Services Research; D006801:Humans; D050997:Nanomedicine / Q000191:economics* / Q000331:legislation & jurisprudence; D011634:Public Health; D018570:Risk Assessment; D012449:Safety / Q000191:economics* / Q000331:legislation & jurisprudence; D006113:United Kingdom